Mga Batayang Estadistika
| CIK | 1574094 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to RenovoRx, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 14, 2025 |
Exhibit 99.1 RenovoRx Reports Commercial Revenue Growth in the Second Quarter 2025 and Announces Positive Independent Data Monitoring Committee Recommendation to Continue Pivotal Phase III TIGeR-PaC Trial Based on Interim Data Review Revenue from RenovoCath® device totaled over $400,000 for the Second Quarter 2025 As of June 30, 2025, the Company had $12.3 million in cash and cash equivalents Mana |
|
| August 14, 2025 |
Supply Agreement, dated June 5, 2025, between RenovoRx, Inc. and Medical Murray, Inc. Exhibit 10.2 Medical Murray Supply Agreement FINAL Certain identified information has been omitted from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. [***] indicates that information has been redacted. RenovoRx, Inc. and Medical Murray Inc. Supply Agreement (U.S. Sales Only) This Supply Agreement (the “Agreement”) is entered int |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 RENOVORX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40738 27-1448452 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40738 RENOVORX, |
|
| August 14, 2025 |
Exhibit 10.1 RENOVORX, INC. 2021 OMNIBUS EQUITY INCENTIVE PLAN Amended and Restated on April 29, 2025 Section 1. Purpose of Plan. The name of the Plan is the RenovoRx, Inc. 2021 Omnibus Equity Incentive Plan (the “Plan”). The purposes of the Plan are to (i) provide an additional incentive to selected employees, directors, and independent contractors of the Company or its Affiliates whose contribut |
|
| June 27, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) RenovoRx, Inc. (Exact name of registrant as specified in its charter) Table 1 - Newly Registered Securities Fees Previously Paid Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, |
|
| June 27, 2025 |
As filed with the Securities and Exchange Commission on June 27, 2025 As filed with the Securities and Exchange Commission on June 27, 2025 Registration No. |
|
| June 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2025 (June 24, 2025) RENOVORX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40738 27-1448452 (State or other jurisdiction of incorporation) (Commi |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40738 RENOVORX, |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 RENOVORX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40738 27-1448452 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 15, 2025 |
Exhibit 99.1 RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights Q1 2025 RenovoCath® Revenues of ~$200,000, Exceeding Expectations and Anticipated to Continue Growing Sequentially with New Customer Purchase Orders and Reorders Cash on Hand of $14.6 Million Anticipated to Fully Fund both RenovoCath Commercialization Scale-up and Continued Progress Towards the Completion of |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| April 1, 2025 |
Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2025 RENOVORX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40738 27-1448452 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| April 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40738 RENOVORX, INC. (Exact name o |
|
| April 1, 2025 |
Exhibit 99.1 RenovoRx Reports Initial Revenues from RenovoCath® Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial Revenues from RenovoCath Expected to Grow Sequentially During 2025 with Expansion of New Customer Purchase Orders and Customer Reorders Completion of TIGeR-PaC Clinical Trial Enrollment and Review of Second Interim Analysis by Data Monitoring |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Pe |
|
| February 10, 2025 |
Exhibit 1.1 Execution Version renovorx, inc. 11,523,810 SHARES OF COMMON STOCK Underwriting Agreement February 6, 2025 Titan Partners Group LLC, a division of American Capital Partners, LLC As the Representative of the several Underwriters listed in Schedule A hereto 4 World Trade Center, 29th Floor New York, NY 10007 Ladies and Gentlemen: RenovoRx, Inc., a Delaware corporation (the “Company”), co |
|
| February 10, 2025 |
RenovoRx Announces Proposed Public Offering February 6, 2025 Exhibit 99.1 RenovoRx Announces Proposed Public Offering February 6, 2025 MOUNTAIN VIEW, Calif.—(BUSINESS WIRE)— RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared delivery platform, today announced that it has commenced an underwritten public offering of shares of i |
|
| February 10, 2025 |
11,523,810 Shares of Common Stock PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (to Prospectus dated November 21, 2022) File No. |
|
| February 10, 2025 |
Form of Underwriter Warrant issued in February 2025 Public Offering Exhibit 4.1 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES FOR WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR TH |
|
| February 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2025 (February 6, 2025) RENOVORX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40738 27-1448452 (State or other jurisdiction of incorporation) |
|
| February 10, 2025 |
Exhibit 99-2 RenovoRx Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock February 6, 2025 MOUNTAIN VIEW, Calif.—(BUSINESS WIRE)— RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared delivery platform, today announced the pricing of a firm c |
|
| February 6, 2025 |
Shares of Common Stock Pre-Funded Warrants to Purchase Shares of Common Stock The information in this preliminary prospectus supplement and the accompanying base prospectus is not complete and may be changed. |
|
| November 14, 2024 |
Exhibit 99.1 RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights Near-Term Revenue Potential with Commercialization Plan for FDA-Cleared RenovoCath® Delivery System in Both Direct and Commercial Partner Channels Renowned Clinical Oncology Sites Participating in Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial; Trial Moving Towards Next Interim Analysis and Full Enrol |
|
| November 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2024 RENOVORX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40738 27-1448452 (State or other jurisdiction of incorporation) (Commission File N |
|
| November 13, 2024 |
Common Stock Purchase Warrant Issued to Medical Murray, Inc., dated September 25, 2024 Exhibit 4.14 CERTAIN IDENTIFIED INFORMATION (INDICATED BY “***”) HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40738 RENOV |
|
| September 25, 2024 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2024 RenovoRx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40738 27-1448452 (State or other Jurisdiction of Incorporation) (Commission File |
|
| September 25, 2024 |
Exhibit 99.1 RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians Company expands relationship with manufacturing partner Medical Murray, and continues active exploration of standalone opportunities for RenovoCath LOS ALTOS, CA – September 25, 2024 – RenovoRx, Inc. (“RenovoRx” or the “Company”) ( |
|
| August 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2024 (August 12, 2024) RenovoRx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40738 27-1448452 (State or other Jurisdiction of Incorporation) (C |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40738 RENOVORX, |
|
| June 7, 2024 |
Exhibit 10.1 RenovoRX, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (the “Agreement”) is made by and between RenovoRx, Inc., a Delaware corporation (the “Company”), and Ron Kocak (“Executive”), effective as of the Effective Date, as defined in Section 7 below. This Agreement provides certain protections to Executive in connection with an involuntary |
|
| June 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2024 (June 6, 2024) RenovoRx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40738 27-1448452 (State or other jurisdiction (Commission (I.R.S. Employ |
|
| May 10, 2024 |
6,133,414 Shares of Common Stock 6,645,354 Shares of Common Stock Issuable Upon Exercise of Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-278841 PROSPECTUS 6,133,414 Shares of Common Stock 6,645,354 Shares of Common Stock Issuable Upon Exercise of Warrants This prospectus relates to the resale by the selling stockholders named herein, including their transferees, assigns, pledgees or donees, or their respective successors, of up to (i) 6,133,414 shares (the “Shares”) of our commo |
|
| May 10, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-278964 PROSPECTUS 6,960,864 Shares of Common Stock 951,500 Shares of Common Stock Issuable Upon Exercise of Pre-Funded Warrant 7,912,364 Shares of Common Stock Issuable Upon Exercise of Series A Warrants 3,956,182 Shares of Common Stock Issuable Upon Exercise of Series B Warrants 701,243 Shares of Common Stock Issuable Upon Exercise of Placemen |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40738 RENOVORX, |
|
| May 8, 2024 |
RENOVORX, INC. 4546 El Camino Real, Suite B1 Los Altos, CA 94022 RENOVORX, INC. 4546 El Camino Real, Suite B1 Los Altos, CA 94022 May 8, 2024 VIA EDGAR U.S. SECURITIES AND EXCHANGE COMMISSION Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549 Attention: Tamika Sheppard Re: RenovoRx, Inc. Registration Statement on Form S-3 Filed April 26, 2024 File No. 333-278964 Dear Ms. Sheppard: Pursuant to Rule 461 under the Secur |
|
| May 8, 2024 |
RENOVORX, INC. 4546 El Camino Real, Suite B1 Los Altos, CA 94022 RENOVORX, INC. 4546 El Camino Real, Suite B1 Los Altos, CA 94022 May 8, 2024 VIA EDGAR U.S. SECURITIES AND EXCHANGE COMMISSION Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549 Attention: Chris Edwards Re: RenovoRx, Inc. Registration Statement on Form S-3 Filed April 19, 2024 File No. 333-278841 Dear Mr. Edwards: Pursuant to Rule 461 under the Securiti |
|
| May 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2024 (April 29, 2024) RenovoRx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40738 27-1448452 (State or other Jurisdiction of Incorporation) (Commis |
|
| May 3, 2024 |
Letter from Baker Tilly US, LLP, dated May 3, 2024 Exhibit 16.1 Baker Tilly US, LLP 18500 Von Karman Ave, 10th Fl. Irvine, CA 92612 United States of America T: +1 (949) 222 2999 F: +1 (949) 222 2989 bakertilly.com May 3, 2024 Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Dear Ladies and Gentleman: We are the independent registered public accounting firm for RenovoRx, Inc. (the “Company”). We have read the Company’s discl |
|
| April 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| April 26, 2024 |
Exhibit 107 Calculation of Filing Fee Table S-3 (Form Type) RenovoRx, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Equity Common Stock 457 (c) 20 |
|
| April 26, 2024 |
As filed with the Securities and Exchange Commission on April 26, 2024 As filed with the Securities and Exchange Commission on April 26, 2024 Registration No. |
|
| April 19, 2024 |
Exhibit 107 Calculation of Filing Fee Table S-3 (Form Type) RenovoRx, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Equity Common Stock 457 (c) 12 |
|
| April 19, 2024 |
As filed with the Securities and Exchange Commission on April 19. 2024 As filed with the Securities and Exchange Commission on April 19. 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 RenovoRx, Inc. (Exact name of Registrant as specified in its charter) Delaware 27-1448452 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer |
|
| April 18, 2024 |
RenovoRx Regains Compliance with Nasdaq Stockholders’ Equity Requirement Exhibit 99.1 RenovoRx Regains Compliance with Nasdaq Stockholders’ Equity Requirement LOS ALTOS, CA – April 18, 2024 – RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that, in light of its recent successful fundraising activity, it has recei |
|
| April 18, 2024 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2024 (April 17, 2024) RenovoRx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40738 27-1448452 (State or other Jurisdiction of Incorporation) (Com |
|
| April 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 16, 2024 RenovoRx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40738 27-1448452 (State or other Jurisdiction of Incorporation) (Commission File Numb |
|
| April 15, 2024 |
Exhibit 99.1 RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026 With $17.2 million in gross proceeds raised since the beginning of 2024, RenovoRx has sufficient funding to advance pivotal Phase III clinical trial and expand development pipeline into additional cancer indications LOS ALTOS, CA – April 15, 2024 – RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNX |
|
| April 15, 2024 |
Form of Series A Warrant to Purchase Common Stock of RenovoRx, Inc. Exhibit 10.3 Warrant Number A- THE WARRANT REPRESENTED BY THIS CERTIFICATE AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION. THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF MAY NOT BE OFFERED, SOLD, PLEDGED, ASSIGNED OR OTHERWISE TRANS |
|
| April 15, 2024 |
Form of Series B Warrant to Purchase Common Stock of RenovoRx, Inc. Exhibit 10.4 Warrant Number B- THE WARRANT REPRESENTED BY THIS CERTIFICATE AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION. THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF MAY NOT BE OFFERED, SOLD, PLEDGED, ASSIGNED OR OTHERWISE TRANS |
|
| April 15, 2024 |
Form of Pre-Funded Common Stock Purchase Warrant of RenovoRx, Inc. Exhibit 10.2 THE WARRANT REPRESENTED BY THIS CERTIFICATE AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION. THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF MAY NOT BE OFFERED, SOLD, PLEDGED, ASSIGNED OR OTHERWISE TRANSFERRED UNLESS (1) |
|
| April 15, 2024 |
Form of Placement Agent Warrant to Purchase Common Stock of RenovoRx, Inc. Exhibit 10.5 Warrant Number PA- THE WARRANT REPRESENTED BY THIS CERTIFICATE AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION. THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF MAY NOT BE OFFERED, SOLD, PLEDGED, ASSIGNED OR OTHERWISE TRAN |
|
| April 15, 2024 |
Form of Subscription Agreement Exhibit 10.1 FORM OF SUBSCRIPTION AGREEMENT RenovoRx, Inc. 4546 El Camino Real, Suite B1 Los Altos, CA 94022 Ladies and Gentlemen: All initially capitalized terms not otherwise defined herein shall have the meanings given to those terms in Schedule I annexed hereto. 1. Subscription. (a) The undersigned (the “Purchaser”), intending to be legally bound, hereby irrevocably agrees to purchase from Ren |
|
| April 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2024 (April 11, 2024) RenovoRx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40738 27-1448452 (State or other Jurisdiction of Incorporation) (Com |
|
| April 12, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) RenovoRx, Inc. (Exact name of registrant as specified in its charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.0001 per |
|
| April 12, 2024 |
As filed with the Securities and Exchange Commission on April 12, 2024 As filed with the Securities and Exchange Commission on April 12, 2024 Registration No. |
|
| April 9, 2024 |
RenovoRx Announces $11.1 Million At Market Private Placement Exhibit 99.1 RenovoRx Announces $11.1 Million At Market Private Placement ● Cash position now expected to fund current operating plan into 2026 ● Financing provides cash runway to advance the ongoing pivotal Phase III TIGeR-PaC trial through the second interim readout and towards completion of the trial ● Financing also enables the expansion of RenovoRx’s TAMPTM (Trans-Arterial Micro-Perfusion) cl |
|
| April 9, 2024 |
Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 9, 2024 (April 4, 2024) RenovoRx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40738 27-1448452 (State or other Jurisdiction of Incorporation) (Commi |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40738 RENOVORX, INC. (Exact name o |
|
| April 1, 2024 |
Amended and Restated Outside Director Compensation Policy Exhibit 10.3 RenovoRx, INC. OUTSIDE DIRECTOR COMPENSATION POLICY Initially Adopted and Approved by the Board of Directors on September 30, 2021; amended and restated September 29, 2022; most recently amended and restated September 7, 2023 (the “Restatement Date”) RenovoRx, Inc. (the “Company”) believes that providing cash and equity compensation to its members of the Board of Directors (the “Board |
|
| April 1, 2024 |
Exhibit 19.1 RENOVORX, INC. INSIDER TRADING POLICY (As Amended on September 7, 2023) 1. PURPOSE This Insider Trading Policy (this “Policy”) states the policy with respect to transactions in the securities of RenovoRx, Inc. (the “Company”), and the handling of confidential information about the Company and other companies with which the Company does business. The Company’s Board of Directors has ad |
|
| April 1, 2024 |
Policy Related to Recovery of Erroneously Awarded Compensation, adopted September 7, 2023 Exhibit 97.1 renovorx, Inc. COMPENSATION RECOVERY POLICY As adopted on September 7, 2023 RenovoRx, Inc. (the “Company”) is committed to strong corporate governance. As part of this commitment, the Company’s Board of Directors (the “Board”) has adopted this clawback policy called the Compensation Recovery Policy (the “Policy”). The Policy is intended to further the Company’s pay-for-performance phi |
|
| March 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2024 (March 8, 2024) RenovoRx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40738 27-1448452 (State or other Jurisdiction of Incorporation) (Comm |
|
| March 14, 2024 |
Amended and Restated Offer Letter, by and between RenovoRx, Inc. and Leesa Gentry Exhibit 10.1 RenovoRx 4546 El Camino Real, Ste. B1 Los Altos, CA 94022 www.renovorx.com March 8, 2024 Leesa Gentry Re: Amended and Restated Offer Letter Dear Leesa: This Amended and Restated Offer Letter amends, restates and replaces that certain offer letter, dated March 21, 2023 (the “Original Offer Letter”), between yourself and RenovoRx, Inc. (the “Company”). Upon the mutual execution of this |
|
| February 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2024 (February 16, 2024) RenovoRx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40738 27-1448452 (State or other Jurisdiction of Incorporation |
|
| February 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2024 (February 5, 2024) RenovoRx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40738 27-1448452 (State or other Jurisdiction of Incorporation) |
|
| February 9, 2024 |
Amended and Restated Offer Letter, by and between RenovoRx, Inc. and Ronald B. Kocak Exhibit 10.1 RenovoRx 4546 El Camino Real, Ste. B1 Los Altos, CA 94022 www.renovorx.com February 9, 2024 Ronald B. Kocak, CPA, CGMA 43092 Binkley Circle Leesburg, VA 20176 Re: Amended and Restated Offer Letter Dear Ron: This Amended and Restated Offer Letter amends, restates and replaces that certain offer letter, dated July 18, 2022 (the “Original Offer Letter”), between yourself and RenovoRx, In |
|
| January 29, 2024 |
RenovoRx Placement Agent Warrant Exhibit 10.5 THE WARRANT REPRESENTED BY THIS CERTIFICATE AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION. THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF MAY NOT BE OFFERED, SOLD, PLEDGED, ASSIGNED OR OTHERWISE TRANSFERRED UNLESS (1) |
|
| January 29, 2024 |
Exhibit 10.2 RenovoRx, Inc. 4546 El Camino Real, Suite B1 Los Altos, CA 94022 January 12, 2024 Re: Extension of Offering/Placement Agent Participants Thank you for your interest in the RenovoRx, Inc. (the “Company”) private placement offering (the “Offering”). We are writing to inform you that pursuant to Section 2 of the Subscription Agreement for the Offering the Company has decided to extend th |
|
| January 29, 2024 |
Form of Subscription Agreement Exhibit 10.1 SUBSCRIPTION AGREEMENT RenovoRx, Inc. 4546 El Camino Real, Suite B1 Los Altos, CA 94022 Ladies and Gentlemen: All initially capitalized terms not otherwise defined herein shall have the meanings given to those terms in Schedule I annexed hereto. 1. Subscription. The undersigned (the “Purchaser”), intending to be legally bound, hereby irrevocably agrees to purchase from RenovoRx, Inc., |
|
| January 29, 2024 |
Warrant to Purchase Common Stock of RenovoRx, Inc. Exhibit 10.3 Warrant Number THE WARRANT REPRESENTED BY THIS CERTIFICATE AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) OR THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION. THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF MAY NOT BE OFFERED, SOLD, PLEDGED, ASSIGNED OR OTHERWISE TRANSFER |
|
| January 29, 2024 |
Exhibit 10.4 November 14, 2023 STRICTLY CONFIDENTIAL Shaun Bagai RenovoRx, Inc. 4546 El Camino Real, Suite B1 Los Altos, CA 94022 PLACEMENT AGENT AGREEMENT This Placement Agent Agreement (“Agreement”) is made by and between RenovoRx Inc., a Delaware corporation (the “Company”), and Paulson Investment Company, LLC, a Delaware limited liability company (the “Placement Agent”), as of the date first a |
|
| January 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2024 (January 25, 2024) RenovoRx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40738 27-1448452 (State or other Jurisdiction of Incorporation) |
|
| January 29, 2024 |
Exhibit 99.1 RenovoRx Closes $6.1 Million Private Placement With Material Participation From Insiders, Offering Proceeds to Help Drive Company Towards Second Interim Analysis of the Pivotal TIGeR-PaC Phase III Clinical Trial by Late 2024 LOS ALTOS, Calif. – January 29, 2024 – RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel pr |
|
| January 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2024 (December 26, 2023) RenovoRx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40738 27-1448452 (State or other Jurisdiction of Incorporation) |
|
| December 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2023 (December 15, 2023) RenovoRx, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40738 27-1448452 (State or other Jurisdiction of Incorporation |
|
| November 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| November 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 RENOVORX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40738 27-1448452 (State or other jurisdiction of incorporation) (Commission File N |
|
| November 14, 2023 |
Exhibit 99.1 RenovoRx Reports Third Quarter 2023 Financial Results and Operational Highlights Collaboration with Imugene further validates TAMPTM (Trans-Arterial Micro-Perfusion) and will expand use of RenovoRx’s delivery platform beyond chemotherapy to immunotherapy. The TAMP therapy platform is in a Phase III clinical trial for the treatment of Pancreatic Cancer, interim analysis was completed i |
|
| November 13, 2023 |
Outside Director Compensation Policy Exhibit 10.4 RenovoRx, INC. OUTSIDE DIRECTOR COMPENSATION POLICY Initially Adopted and Approved by the Board of Directors on September 30, 2021; amended and restated September 29, 2022; most recently amended and restated September 7, 2023 (the “Restatement Date”) RenovoRx, Inc. (the “Company”) believes that providing cash and equity compensation to its members of the Board of Directors (the “Board |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended SEPTEMBER 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40738 RENOV |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2023 RENOVORX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40738 27-1448452 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| September 11, 2023 |
Amended and Restated Bylaws of RenovoRx, Inc. Exhibit 3.1 RENOVORX, INC. a Delaware Corporation (the “Corporation”) AMENDED AND RESTATED BYLAWS As Adopted March 24, 2022 As Amended September 7, 2023 ARTICLE I MEETINGS OF STOCKHOLDERS Section 1.1 Place of Meetings. Meetings of stockholders shall be held at any place, within or outside the State of Delaware, designated by the board of directors of the Corporation (the “Board of Directors”). The |
|
| September 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2023 RENOVORX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40738 27-1448452 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2023 RENOVORX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40738 27-1448452 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2023 RENOVORX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40738 27-1448452 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 17, 2023 |
Exhibit 99.1 RenovoRx Reports Second Quarter 2023 Financial Results and Operational Highlights Presented positive Phase III TIGeR-PaC interim study results observing 8-month delay in cancer progression, concordant with 6-month overall survival benefit and 65% reduction in adverse effects over standard of care. Announced collaboration with Imugene to explore delivery of oncolytic virus therapy usin |
|
| August 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended JUNE 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40738 RENOVORX, |
|
| August 16, 2023 |
Form of Amendment to Change of Control and Severance Agreement, dated June 1, 2023 Exhibit 10.3 AMENDMENT TO CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Amendment to the Change in Control Severance Agreement (this “Amendment”) is entered into as of (the “Effective Date”) by and between (“Executive”) and RenovoRx, Inc. (the “Company” and together with Executive, the “Parties”) on the dates set forth below. WHEREAS, the Parties previously entered into a Change in Control and Se |
|
| August 15, 2023 |
SEC FILE NUMBER 001-40738 CUSIP NUMBER 75989R 107 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| June 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2023 RENOVORX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40738 27-1448452 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| June 29, 2023 |
Press Release, dated June 29, 2023 Exhibit 99.1 |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2023 RENOVORX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40738 27-1448452 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 19, 2023 |
Secondary Offering of 1,947,040 Shares of Common Stock Issuable Upon Exercise of Warrants Filed Pursuant to Rule 424(b)(3) Registration No. 333-271882 PROSPECTUS Secondary Offering of 1,947,040 Shares of Common Stock Issuable Upon Exercise of Warrants This prospectus relates to the resale by the selling stockholder named herein, including its transferees, pledgees or donees, or their respective successors, of up to 1,947,040 shares (the “Shares”) of our common stock, par value $0.0001 |
|
| May 17, 2023 |
RenovoRx, Inc. 4546 El Camino Real, Suite B1 Los Altos, California 94022 May 17, 2023 RenovoRx, Inc. 4546 El Camino Real, Suite B1 Los Altos, California 94022 May 17, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: RenovoRx, Inc. Registration Statement on Form S-3 Filed May 12, 2023 File No. 333-271882 Acceleration Request Requested Date: May 19, 2023 Requested Time: 4:00 p.m. Eastern Time, or as soon t |
|
| May 15, 2023 |
Exhibit 99.1 RenovoRx Reports First Quarter 2023 Financial Results and Operational Highlights Announced Phase III Interim Study Analysis Results: 60% Survival Benefit and Greater than 65% Reduction in Side Effects with RenovoGemTM Compared to Systemic Chemotherapy in Pancreatic Cancer Los Altos, CA, May 15, 2023 - RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical com |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2023 RENOVORX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40738 27-1448452 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended MARCH 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40738 RENOVORX, |
|
| May 12, 2023 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-3 RENOVORX, INC. Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward In |
|
| May 12, 2023 |
As filed with the Securities and Exchange Commission on May 12, 2023 As filed with the Securities and Exchange Commission on May 12, 2023 Registration No. |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Stat |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2023 (April 25, 2023) RENOVORX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40738 27-1448452 (State or other jurisdiction of incorporation) (Com |
|
| April 27, 2023 |
Exhibit 99.1 RenovoRx Appoints Former Chief Medical Officer of Schering-Plough, Robert J. Spiegel, MD, FACP, to Board of Directors Los Altos, CA, April 27, 2023 - RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on targeted drug-delivery with an initial application in locally advanced pancreatic cancer (LAPC), announced today that Robert J. Spiegel, |
|
| April 3, 2023 |
Filed Pursuant to Rule 424(b)(5) File No. 333- 268302 PROSPECTUS SUPPLEMENT (to Prospectus dated November 21, 2022) 1,000,000 SHARES OF COMMON STOCK PRE-FUNDED WARRANTS TO PURCHASE UP TO 557,632 SHARES OF COMMON STOCK We are offering 1,000,000 shares (“Shares”) of our common stock, par value $0.0001 per share, and pre-funded warrants (“Pre-funded Warrants”) to purchase up to 557,632 shares of comm |
|
| April 3, 2023 |
Exhibit 99.1 RenovoRx, Inc. Announces $5 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules LOS ALTOS, Calif., March 30, 2023 — RenovoRx, Inc. (the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, today announced that it has entered into a definitive securities purchase agreement with a certain institutional investor |
|
| April 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2023 RENOVORX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40738 27-1448452 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| April 3, 2023 |
Form of Securities Purchase Agreement Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 30, 2023, between RenovoRx, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set fort |
|
| April 3, 2023 |
As filed with the Securities and Exchange Commission on March 31, 2023 As filed with the Securities and Exchange Commission on March 31, 2023 Registration No. |
|
| April 3, 2023 |
Form of Common Stock Purchase Warrant Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| April 3, 2023 |
Form of Pre-Funded Common Stock Purchase Warrant Exhibit 4.1 PREFUNDED COMMON STOCK PURCHASE WARRANT RenovoRx, Inc. Warrant Shares: Initial Exercise Date: April , 2023 THIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof ( |
|
| April 3, 2023 |
Exhibit 10.1 PLACEMENT AGENCY AGREEMENT March 30, 2023 Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Ladies and Gentlemen: Introduction. Subject to the terms and conditions herein (this “Agreement”), RenovoRx, Inc., a Delaware corporation (the “Company”), hereby agrees to sell up to an aggregate of $4,999,942.96 of registered and unregistered securities of th |
|
| March 31, 2023 |
As filed with the Securities and Exchange Commission on March 31, 2023 S-8 1 forms-8.htm As filed with the Securities and Exchange Commission on March 31, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 RENOVORX, INC. (Exact name of registrant as specified in its charter) Delaware 27-1448452 (State or other jurisdiction of incorporation or organization) |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2022 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-40738 RENOVORX, INC. (Exact name o |
|
| March 31, 2023 |
Amended and Restated Outside Director Compensation Policy Exhibit 10.3 RenovoRx, INC. OUTSIDE DIRECTOR COMPENSATION POLICY Initially Adopted and Approved by the Board of Directors on September 30, 2021; most recently amended and restated September 29, 2022 (the “Restatement Date”) RenovoRx, Inc. (the “Company”) believes that providing cash and equity compensation to its members of the Board of Directors (the “Board,” and members of the Board, the “Direct |
|
| March 31, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) RenovoRx, Inc. (Exact name of registrant as specified in its charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.0001 per |
|
| March 2, 2023 |
Exhibit 99.1 RenovoRx Reports Full Year 2022 Financial Results and Achievement of Important Phase III Clinical Study Milestone First of Two Planned Interim Analyses Triggered Company and Data Monitoring Committee Conducting Review Results of Analysis Forthcoming Los Altos, CA, March 2, 2023 - RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the lo |
|
| March 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 RENOVORX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40738 27-1448452 (State or other jurisdiction (Commission (I.R.S. Employer of incorpor |
|
| February 14, 2023 |
RNXT / RenovoRx, Inc. / Agah Ramtin Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* RENOVORX, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 75989R 107 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate b |
|
| January 18, 2023 |
Exhibit 99.1 RenovoRx Announces Initial Results in Pharmacokinetic (PK) Substudy: Data on RenovoGemTM Supports Potential for RenovoTAMP® Therapy Platform to Increase Local Gemcitabine (Chemotherapy) Delivery and Decrease Side Effects of Pancreatic Cancer Treatment Researchers presenting four abstracts on different substudies, including the preliminary PK substudy, at the ASCO GI Cancers Symposium |
|
| January 18, 2023 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2023 RENOVORX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40738 27-1448452 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 22, 2022 |
424B3 1 form424b3.htm Filed Pursuant to Rule 424(b)(3) Registration No. 333-268316 PROSPECTUS Primary Offering of 2,786,995 Shares of Common Stock Issuable Upon Exercise of Warrants Secondary Offering of 708,820 Warrants to Purchase Shares of Common Stock and 2,786,995 Shares of Common Stock This registration statement relates to the registration by us of up to 2,786,995 shares of our Common Stock |
|
| November 18, 2022 |
RenovoRx, Inc. 4546 El Camino Real, Suite B1 Los Altos, California 94022 November 18, 2022 RenovoRx, Inc. 4546 El Camino Real, Suite B1 Los Altos, California 94022 November 18, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: RenovoRx, Inc. Registration Statement on Form S-1 Filed November 10, 2022 File No. 333-268316 Acceleration Request Requested Date: November 21, 2022 Requested Time: 4:00 p.m. Eastern Tim |
|
| November 18, 2022 |
RenovoRx, Inc. 4546 El Camino Real, Suite B1 Los Altos, California 94022 November 18, 2022 RenovoRx, Inc. 4546 El Camino Real, Suite B1 Los Altos, California 94022 November 18, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: RenovoRx, Inc. Registration Statement on Form S-3 Filed November 10, 2022 File No. 333-268302 Acceleration Request Requested Date: November 21, 2022 Requested Time: 4:00 p.m. Eastern Tim |
|
| November 14, 2022 |
RenovoRx Reports Third Quarter 2022 Financial Results Exhibit 99.1 RenovoRx Reports Third Quarter 2022 Financial Results Los Altos, CA, November 14, 2022 - RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP?) therapy platform, today reported its financial results for the quarter ended September 30, |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended SEPTEMBER 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40738 RENOV |
|
| November 14, 2022 |
Outside Director Compensation Policy Exhibit 10.3 RenovoRx, INC. OUTSIDE DIRECTOR COMPENSATION POLICY Initially Adopted and Approved by the Board of Directors on September 30, 2021; most recently amended and restated September 29, 2022 (the ?Restatement Date?) RenovoRx, Inc. (the ?Company?) believes that providing cash and equity compensation to its members of the Board of Directors (the ?Board,? and members of the Board, the ?Direct |
|
| November 14, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 RENOVORX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40738 27-1448452 (State or other jurisdiction of incorporation) (Commission File N |
|
| November 10, 2022 |
As filed with the Securities and Exchange Commission on November 10, 2022 As filed with the Securities and Exchange Commission on November 10, 2022 Registration No. |
|
| November 10, 2022 |
Exhibit 4.8 RenovoRx, INC. INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Article I DEFINITIONS AND INCORPORATION BY REFERENCE 6 Section 1.1 Definitions. 6 Section 1.2 Other Definitions. 8 Section 1.3 Incorporation by Reference of Trust Indenture Act. 9 Section 1.4 Rules of Construction. 9 Article II THE SECURITIES 9 Section 2.1 Issuable in Series. 9 Section 2.2 Establishment of Terms of |
|
| November 10, 2022 |
EX-FILING FEES 5 ex107.htm Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) RenovoRx, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Proposed Maximum Aggregate Offering Price Fee R |
|
| November 10, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) RENOVORX, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry For |
|
| November 10, 2022 |
As filed with the Securities and Exchange Commission on November 10, 2022 As filed with the Securities and Exchange Commission on November 10, 2022 Registration No. |
|
| September 19, 2022 |
Offer Letter between RenovoRx, Inc. and Angela Gill Nelms Exhibit 10.1 RenovoRx 4546 El Camino Real, Ste. B1 Los Altos, CA 94022 www.renovorx.com AUGUST 15, 2022 Angela Nelms [Contact information on file with the Company] Via Email Re: Offer of Employment with RenovoRx, Inc. Dear Angela: I am pleased to offer you a position with RenovoRx, Inc. (the ?Company?), with a start date of September 19, 2022 (the ?Start Date?). 1. Title; Position; Location. You w |
|
| September 19, 2022 |
RenovoRx Appoints Angela Gill Nelms as Chief Operating Officer Exhibit 99.1 RenovoRx Appoints Angela Gill Nelms as Chief Operating Officer Los Altos, CA, September 19, 2022 - RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP?) therapy platform, today announced that Angela Gill Nelms has joined the company a |
|
| September 19, 2022 |
Exhibit 10.2 RenovoRX, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (the ?Agreement?) is made by and between RenovoRx, Inc., a Delaware corporation (the ?Company?), and Angela Gill Nelms (?Executive?), effective as of the Effective Date, as defined in Section 7 below. This Agreement provides certain protections to Executive in connection with an inv |
|
| September 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2022 RENOVORX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40738 27-1448452 (State or other jurisdiction of incorporation) (Commission File |
|
| August 15, 2022 |
RenovoRx Reports Second Quarter 2022 Financial Results Exhibit 99.1 RenovoRx Reports Second Quarter 2022 Financial Results Los Altos, CA, August 15, 2022 - RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMPTM) therapy platform, today reported its financial results for the quarter ended June 30, 2022. |
|
| August 15, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 RENOVORX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40738 27-1448452 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended JUNE 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40738 RENOVORX, |
|
| July 19, 2022 |
Exhibit 99.1 RenovoRx Appoints James Ahlers as Chief Financial Officer Expands Finance Team with Addition of Ronald B. Kocak, CPA as Vice President and Controller Los Altos, CA, July 19, 2022 - RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today is announcing the appointment of James Ahlers as Chief Financial Officer (CFO), effective July 15, |
|
| July 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2022 RENOVORX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40738 27-1448452 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| July 19, 2022 |
Consulting Agreement by and between RenovoRx, Inc. and Danforth Advisors, LLC, dated April 25, 2022 Exhibit 10.1 CONSULTING AGREEMENT This Consulting Agreement (the ?Agreement?) is made as of April 25, 2022 (the ?Effective Date?), by and between RenovoRx, Inc., a Delaware corporation, with its principal place of business being 4546 El Camino Real, Suite B1, Los Altos, CA 94022 (the ?Company?) and Danforth Advisors, LLC, a Massachusetts limited liability company, with its principal place of busin |
|
| June 9, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2022 RENOVORX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40738 27-1448452 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 16, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2022 RENOVORX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40738 27-1448452 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 16, 2022 |
RenovoRx Reports First Quarter 2022 Financial Results Exhibit 99.1 RenovoRx Reports First Quarter 2022 Financial Results Los Altos, CA, May 16, 2022 - RenovoRx, Inc. (?RenovoRx? or the ?Company?) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today is reporting its financial results for the quarter ended March 31, 2022. ?As we report our Q1 2022 results, we acknowledge that May is Cancer Research Month. RenovoRx |
|
| May 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40738 RENOVORX, |
|
| April 29, 2022 |
DEF 14A 1 formdef14-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2 |
|
| March 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2022 RENOVORX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40738 27-1448452 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| March 30, 2022 |
EX-10.2 4 ex10-2.htm Exhibit 10.2 RENOVORX, INC. 2021 OMNIBUS EQUITY INCENTIVE PLAN Section 1. Purpose of Plan. The name of the Plan is the RenovoRx, Inc. 2021 Omnibus Equity Incentive Plan (the “Plan”). The purposes of the Plan are to (i) provide an additional incentive to selected employees, directors, and independent contractors of the Company or its Affiliates whose contributions are essential |
|
| March 30, 2022 |
RenovoRx Reports Full Year 2021 Financial Results EX-99.1 2 ex99-1.htm Exhibit 99.1 RenovoRx Reports Full Year 2021 Financial Results Los Altos, CA, March 30, 2022 - RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today is reporting its financial results for the year ended December 31, 2021. “2021 was a transformative year for RenovoRx. We successfully closed on ou |
|
| March 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2021 ? Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-40738 RENOVORX, INC. (Exact name o |
|
| March 30, 2022 |
As filed with the Securities and Exchange Commission on March 30, 2022 As filed with the Securities and Exchange Commission on March 30, 2022 Registration No. |
|
| March 30, 2022 |
EX-FILING FEES 5 ex107.htm Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) RenovoRx, Inc. (Exact name of registrant as specified in its charter) Table 1 - Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common S |
|
| March 30, 2022 |
Amended and Restated Bylaws of RenovoRx, Inc. Exhibit 3.2 RENOVORX, INC. a Delaware Corporation (the ?Corporation?) AMENDED AND RESTATED BYLAWS As Adopted March 24, 2022 ARTICLE I MEETINGS OF STOCKHOLDERS Section 1.1 Place of Meetings. Meetings of stockholders shall be held at any place, within or outside the State of Delaware, designated by the board of directors of the Corporation (the ?Board of Directors?). The Board of Directors may, in i |
|
| March 30, 2022 |
Amended and Restated Outside Director Compensation Policy EX-10.3 5 ex10-3.htm Exhibit 10.3 RenovoRx, INC. OUTSIDE DIRECTOR COMPENSATION POLICY Initially Adopted and Approved by the Board of Directors on September 30, 2021; most recently amended and restated February 10, 2022 (the “Restatement Date”) RenovoRx, Inc. (the “Company”) believes that providing cash and equity compensation to its members of the Board of Directors (the “Board,” and members of th |
|
| March 30, 2022 |
Exhibit 10.7 AMENDMENT TO CONSULTING aGREEMENT This Fourth Amendment (the ?Fourth Amendment?) by and between RenovoRx, Inc. (the ?Company?) and Ramtin Agah (?Consultant?) (together, the ?Parties?) amends the Consulting Agreement by and between the Parties dated January 1, 2018 (?Consulting Agreement?), as amended by the Second Amendment to the Consulting Agreement, effective August 1, 2019 (the ?S |
|
| March 30, 2022 |
Exhibit 4.6 Description of Securities The following summary of the material terms of the capital stock of RenovoRx, Inc. (?we,? ?our,? ?us? or the ?Company?) is not intended to be a complete description of all of the rights and preferences of such securities. Because it is only a summary, it does not contain all of the information that may be important to you, and is qualified in its entirety by r |
|
| February 14, 2022 |
RNXT / RenovoRx, Inc. / Najmabadi Kamran Passive Investment SC 13G 1 formsc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* RENOVORX, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 75989R 107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box t |
|
| February 14, 2022 |
RNXT / RenovoRx, Inc. / Agah Ramtin Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* RENOVORX, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 75989R 107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| February 10, 2022 |
RNXT / RenovoRx, Inc. / BOSTON SCIENTIFIC CORP - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* RENOVORX, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 75989R107 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| December 10, 2021 |
EX-16.1 2 ex16-1.htm Exhibit 16.1 |
|
| December 10, 2021 |
Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2021 RENOVORX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40708 27-1448452 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 15, 2021 |
RenovoRx Announces Third Quarter 2021 Financial Results Exhibit 99.1 FOR IMMEDIATE RELEASE RenovoRx Announces Third Quarter 2021 Financial Results Los Altos, CA, November 15, 2021 ? RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today reported its unaudited financial results for the third quarter ended September 30, 2021. ?The third quarter of 2021 marked an important juncture in the growth of our c |
|
| November 15, 2021 |
EX-10.8 10 ex10-8.htm Exhibit 10.8 RenovoRX, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (the “Agreement”) is made by and between RenovoRx, Inc., a Delaware corporation (the “Company”), and Ramtin Agah (“Service Provider”), effective as of the Effective Date, as defined in Section 7 below. This Agreement provides certain protections to Service Prov |
|
| November 15, 2021 |
EX-10.7 9 ex10-7.htm Exhibit 10.7 RenovoRX, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (the “Agreement”) is made by and between RenovoRx, Inc., a Delaware corporation (the “Company”), and Shaun R. Bagai (“Executive”), effective as of the Effective Date, as defined in Section 7 below. This Agreement provides certain protections to Executive in conn |
|
| November 15, 2021 |
Amended and Restated Investor Rights Agreement, dated as of April 18, 2018 Exhibit 10.1 RENOVORX, INC. AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT RENOVORX, INC. AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT THIS AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (the ?Agreement?) is entered into as of the 18 day of April, 2018, by and among RenovoRx, Inc., a Delaware corporation (the ?Company?) and the investors listed on Exhibit A hereto, referred to hereinafter as the |
|
| November 15, 2021 |
Outside Director Compensation Policy Exhibit 10.3 RenovoRx, INC. OUTSIDE DIRECTOR COMPENSATION POLICY Adopted and Approved by the Board of Directors on September 30, 2021 RenovoRx, Inc. (the ?Company?) believes that providing cash and equity compensation to its members of the Board of Directors (the ?Board,? and members of the Board, the ?Directors?) represents an effective tool to attract, retain and reward Directors who are not emp |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40708 RENOV |
|
| November 15, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2021 RENOVORX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40708 27-1448452 (State or other jurisdiction of incorporation) (Commission File N |
|
| November 15, 2021 |
Consulting Agreement, by and between RenovoRx, Inc. and Ramtin Agah, M.D., dated January 1, 2018 EX-10.5 7 ex10-5.htm Exhibit 10.5 |
|
| November 15, 2021 |
Confirmatory Offer Letter, by and between RenovoRx, Inc. and Shaun Bagai, dated November 11, 2021 Exhibit 10.4 4546 El Camino Real, Ste B1 Los Altos, CA 94022 November 11, 2021 Shaun Bagai Via Email Re: Confirmatory Employment Letter Dear Shaun: This confirmatory employment letter agreement (the ?Agreement?) is entered into between Shaun Bagai (?you?) and RenovoRx, Inc. (the ?Company? or ?we?), effective as of November 11, 2021 (the ?Effective Date?), to confirm the terms and conditions of you |
|
| November 15, 2021 |
2021 Omnibus Equity Incentive Plan and Forms of Stock Option Grant Notice and Option Agreement Exhibit 10.2 RENOVORX, INC. 2021 OMNIBUS EQUITY INCENTIVE PLAN Section 1. Purpose of Plan. The name of the Plan is the RenovoRx, Inc. 2021 Omnibus Equity Incentive Plan (the ?Plan?). The purposes of the Plan are to (i) provide an additional incentive to selected employees, directors, and independent contractors of the Company or its Affiliates whose contributions are essential to the growth and su |
|
| November 15, 2021 |
Key Service Provider Incentive Compensation Plan EX-10.9 11 ex10-9.htm Exhibit 10.9 RenovoRx, INC. KEY SERVICE PROVIDER INCENTIVE COMPENSATION PLAN 1. Purposes of the Plan. The Plan is intended to increase stockholder value and the success of the Company by motivating Service Providers to (a) perform to the best of their abilities and (b) achieve the Company’s objectives. 2. Definitions. (a) “Actual Award” means as to any Performance Period, the |
|
| November 15, 2021 |
Exhibit 10.6 AMENDMENT TO CONSULTING aGREEMENT This Third Amendment (the ?Third Amendment?) by and between RenovoRx, Inc. (the ?Company?) and Ramtin Agah (?Consultant?) (together, the ?Parties?) amends the Consulting Agreement by and between the Parties dated January 1, 2018 (?Consulting Agreement?), as amended by the Second Amendment to Consulting Agreement, effective August 1, 2019 (the ?Second |
|
| November 15, 2021 |
Exhibit 4.1 THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?ACT?), OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS (I) A REGISTRATION STATEMENT COVERING SUCH SHARES IS EFFECTIVE UNDER THE |
|
| October 29, 2021 |
As filed with the Securities and Exchange Commission on October 28, 2021 As filed with the Securities and Exchange Commission on October 28, 2021 Registration No. |
|
| August 31, 2021 |
Sixth Amended and Restated Certificate of Incorporation of RenovoRx, Inc. EX-3.1 2 ex3-1.htm Exhibit 3.1 SIXTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF RENOVORX, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) RenovoRx, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify as |
|
| August 31, 2021 |
EX-3.2 3 ex3-2.htm Exhibit 3.2 RENOVORX, INC. a Delaware Corporation (the “Corporation”) AMENDED AND RESTATED BYLAWS As Adopted August 30, 2021 ARTICLE I MEETINGS OF STOCKHOLDERS Section 1.1 Place of Meetings. Meetings of stockholders shall be held at any place, within or outside the State of Delaware, designated by the board of directors of the Corporation (the “Board of Directors”). The Board of |
|
| August 31, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2021 RENOVORX, INC. (Exact name of registrant as specified in its charter) Delaware 001-40708 27-1448452 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 27, 2021 |
Filed Pursuant to Rule 424(b)(4) Registration No. 333-258071 PROSPECTUS 1,850,000 Units, Each Consisting of One Share of Common Stock and One Warrant to Purchase One Share of Common Stock This is our initial public offering. We are offering 1,850,000 of units of securities (the “Units”) pursuant to this prospectus at an initial public offering price of $9.00 per Unit. Prior to this offering, there |
|
| August 25, 2021 |
RenovoRx, Inc. 4546 El Camino Real, Suite B1 Los Altos, CA 94022 CORRESP 1 filename1.htm RenovoRx, Inc. 4546 El Camino Real, Suite B1 Los Altos, CA 94022 August 25, 2021 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Jane Park Re: RenovoRx, Inc. Registration Statement on Form S-1 Filed July 21, 2021 File No. 333-258071 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations |
|
| August 25, 2021 |
As filed with the Securities and Exchange Commission on August 25, 2021. S-1/A 1 forms-1a.htm As filed with the Securities and Exchange Commission on August 25, 2021. No. 333-258071 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 4 To FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 RenovoRx, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 27-1448452 (State or other jurisdiction of incorpor |
|
| August 25, 2021 |
Roth Capital Partners, LLC 888 San Clemente Drive Newport Beach, CA 92660 Roth Capital Partners, LLC 888 San Clemente Drive Newport Beach, CA 92660 August 25, 2021 Securities and Exchange Commission 100 F Street, N. |
|
| August 24, 2021 |
RenovoRx, Inc. 4546 El Camino Real, Suite B1 Los Altos, CA 94022 RenovoRx, Inc. 4546 El Camino Real, Suite B1 Los Altos, CA 94022 August 24, 2021 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Jane Park Re: RenovoRx, Inc. Registration Statement on Form S-1 Filed July 21, 2021 File No. 333-258071 Ladies and Gentlemen: Reference is made to the acceleration request letter of RenovoRx, Inc. (the ?Comp |
|
| August 20, 2021 |
Roth Capital Partners, LLC 888 San Clemente Drive Newport Beach, CA 92660 CORRESP 1 filename1.htm Roth Capital Partners, LLC 888 San Clemente Drive Newport Beach, CA 92660 August 20, 2021 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: RenovoRx, Inc. (the “Company”) Registration Statement on Form S-1 (File No. 333-258071) Ladies and Gentlemen: In connection with the above-captioned registration statement, and pursuant to Rule 461 under t |
|
| August 20, 2021 |
RenovoRx, Inc. 4546 El Camino Real, Suite B1 Los Altos, CA 94022 RenovoRx, Inc. 4546 El Camino Real, Suite B1 Los Altos, CA 94022 August 20, 2021 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Jane Park Re: RenovoRx, Inc. Registration Statement on Form S-1 Filed July 21, 2021 File No. 333-258071 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Ac |
|
| August 19, 2021 |
As filed with the Securities and Exchange Commission on August 19, 2021. As filed with the Securities and Exchange Commission on August 19, 2021. No. 333-258071 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 3 To FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 RenovoRx, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 27-1448452 (State or other jurisdiction of incorporation or organization |
|
| August 12, 2021 |
As filed with the Securities and Exchange Commission on August 11, 2021. S-1/A 1 forms-1a.htm As filed with the Securities and Exchange Commission on August 11, 2021. No. 333-258071 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 To FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 RenovoRx, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 27-1448452 (State or other jurisdiction of incorpor |
|
| August 12, 2021 |
Form of Warrant Agent Agreement (including the terms of the Warrants) Exhibit 4.2 WARRANT AGENT AGREEMENT This Warrant Agent Agreement (this ?Warrant Agreement?), dated as of , 2021 (the ?Issuance Date?) between RenovoRx, Inc., a company incorporated under the laws of the State of Delaware (the ?Company?), and Philadelphia Stock Transfer, Inc. (the ?Warrant Agent?). WHEREAS, pursuant to the terms of that certain Underwriting Agreement (?Underwriting Agreement?), dat |
|
| August 12, 2021 |
Form of Underwriting Agreement. Exhibit 1.1 SHARES of Common Stock, PREFUNDED Warrants, and Warrants of RenovoRx, Inc. UNDERWRITING AGREEMENT , 2021 Roth Capital Partners, LLC As the Representative of the Several underwriters, if any, named in Schedule I hereto c/o Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Ladies and Gentlemen: The undersigned, RenovoRx, Inc., a company incorporated und |
|
| August 12, 2021 |
RenovoRx, Inc. 4546 El Camino Real, Suite B1 Los Altos, CA 94022 RenovoRx, Inc. 4546 El Camino Real, Suite B1 Los Altos, CA 94022 August 12, 2021 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Jane Park Re: RenovoRx, Inc. Registration Statement on Form S-1 Filed July 21, 2021 File No. 333-258071 Ladies and Gentlemen: Reference is made to the acceleration request letter of RenovoRx, Inc. (the “Comp |
|
| August 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 RenovoRx, Inc. (Exact name of registrant as specified in its charter) Delaware 27-1448452 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 4546 El |
|
| August 10, 2021 |
RenovoRx, Inc. 4546 El Camino Real, Suite B1 Los Altos, CA 94022 RenovoRx, Inc. 4546 El Camino Real, Suite B1 Los Altos, CA 94022 August 10, 2021 VIA EDGAR United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Jane Park Re: RenovoRx, Inc. Registration Statement on Form S-1 Filed July 21, 2021 File No. 333-258071 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Ac |
|
| August 10, 2021 |
Roth Capital Partners, LLC 888 San Clemente Drive Newport Beach, CA 92660 CORRESP 1 filename1.htm Roth Capital Partners, LLC 888 San Clemente Drive Newport Beach, CA 92660 August 10, 2021 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: RenovoRx, Inc. (the “Company”) Registration Statement on Form S-1 (File No. 333-258071) Ladies and Gentlemen: In connection with the above-captioned registration statement, and pursuant to Rule 461 under t |
|
| August 5, 2021 |
Exhibit 4.5 EXHIBIT A-2 COMMON STOCK PURCHASE WARRANT RenovoRx, Inc. Warrant Shares: Initial Exercise Date: , 2021 THIS COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the ?Initial E |
|
| August 5, 2021 |
Exhibit 3.3 SIXTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF RENOVORX, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) RenovoRx, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify as follows: 1. The Cor |
|
| August 5, 2021 |
Exhibit 4.1 UNDERWRITER COMMON STOCK PURCHASE WARRANT RenovoRx, Inc. Warrant Shares: Initial Exercise Date: Issue Date: THIS UNDERWRITER COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after 1 (the “Initia |
|
| August 5, 2021 |
Sheppard, Mullin, Richter & Hampton LLP CORRESP 1 filename1.htm Sheppard, Mullin, Richter & Hampton LLP 30 Rockefeller Plaza New York, New York 10112-0015 212.653.8700 main 212.653.8701 fax www.sheppardmullin.com 212.634.3067 direct [email protected] August 5, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Re: RenovoRx, Inc. Registration Statement |
|
| August 5, 2021 |
Form of Underwriting Agreement. Exhibit 1.1 SHARES of Common Stock, PREFUNDED Warrants, and Warrants of RenovoRx, Inc. UNDERWRITING AGREEMENT , 2021 Roth Capital Partners, LLC As the Representative of the Several underwriters, if any, named in Schedule I hereto c/o Roth Capital Partners, LLC 888 San Clemente Drive, Suite 400 Newport Beach, CA 92660 Ladies and Gentlemen: The undersigned, RenovoRx, Inc., a company incorporated und |
|
| August 5, 2021 |
Consent of Executive Officer Nominee EX-99.1 14 ex99-1.htm Exhibit 99.1 Consent of Executive Officer Nominee RenovoRx, Inc. is filing a Registration Statement on Form S-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended, or the Securities Act, in connection with the initial public offering of Common Stock of RenovoRx, Inc. In connection therewith, I hereby consent, pursuant to Rule 438 of the S |
|
| August 5, 2021 |
Form of Indemnification Agreement Exhibit 10.7 RENOVORX, Inc. INDEMNIFICATION AGREEMENT This INDEMNIFICATION AGREEMENT (“Agreement”) is made as of , 2021 by and between RenovoRX, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering the subject matter of this Agreement. RECITALS WHEREAS, highly competent p |
|
| August 5, 2021 |
Client Agreement between RenovoRx, Inc. and LS Associates, Inc. Exhibit 10.12 CLIENT Agreement This Client Agreement (the “Agreement”) entered into as of July 22, 2021 (the “Effective Date”) is a binding contract between RenovoRx, Inc. and its affiliates (“you” or “your”) and LS Associates, a division of LifeSci Advisors, LLC (the “Company,” “we,” or “us”). Please read it carefully and, if you agree to and accept all of its terms and conditions, sign the Agree |
|
| August 5, 2021 |
EX-3.6 4 ex3-6.htm Exhibit 3.6 CERTIFICATE OF SECOND AMENDMENT OF FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF RENOVORX, INC. RenovoRx, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), certifies that: 1. The name of the Company is RenovoRx, Inc. The Company’s original Certificate of Incorporation was filed with the Secretary of State |
|
| August 5, 2021 |
Form of 2021 Equity Incentive Plan Exhibit 10.6 RENOVORX, INC. 2021 OMNIBUS EQUITY INCENTIVE PLAN Section 1. Purpose of Plan. The name of the Plan is the RenovoRx, Inc. 2021 Omnibus Equity Incentive Plan (the “Plan”). The purposes of the Plan are to (i) provide an additional incentive to selected employees, directors, and independent contractors of the Company or its Affiliates whose contributions are essential to the growth and su |
|
| August 5, 2021 |
As filed with the Securities and Exchange Commission on August 5, 2021. As filed with the Securities and Exchange Commission on August 5, 2021. No. 333-258071 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 To FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 RenovoRx, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 27-1448452 (State or other jurisdiction of incorporation or organization) |
|
| August 5, 2021 |
Specimen Stock Certificate evidencing the Shares of Common Stock EX-4.4 7 ex4-4.htm Exhibit 4.4 |
|
| August 5, 2021 |
Exhibit 4.3 EXHIBIT A-2 PREFUNDED COMMON STOCK PURCHASE WARRANT RenovoRx, Inc. Warrant Shares: Initial Exercise Date: , 2021 THIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date he |
|
| July 21, 2021 |
Exhibit 10.1 RenovoRx, Inc. Amended and Restated 2013 Equity Incentive Plan Termination Date: January 22, 2023 1. General. (a) Eligible Stock Award Recipients. The persons eligible to receive Stock Awards are Employees, Directors and Consultants. (b) Available Stock Awards. The Plan provides for the grant of the following Stock Awards: (i) Incentive Stock Options, (ii) Nonstatutory Stock Options, |
|
| July 21, 2021 |
Form of 2021 Equity Incentive Plan EX-10.6 13 ex10-6.htm Exhibit 10.6 RENOVORX, INC. 2021 OMNIBUS EQUITY INCENTIVE PLAN Section 1. Purpose of Plan. The name of the Plan is the RenovoRx, Inc. 2021 Omnibus Equity Incentive Plan (the “Plan”). The purposes of the Plan are to (i) provide an additional incentive to selected employees, directors, and independent contractors of the Company or its Affiliates whose contributions are essentia |
|
| July 21, 2021 |
EX-3.3 4 ex3-3.htm Exhibit 3.3 SIXTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF RENOVORX, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) RenovoRx, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify as |
|
| July 21, 2021 |
Certificate of Amendment of Fifth Amended and Restated Certificate of Incorporation of the Company Exhibit 3.2 CERTIFICATE OF AMENDMENT OF FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF RENOVORX, INC. RenovoRx, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), certifies that: 1. The name of the Company is RenovoRx, Inc. The Company’s original Certificate of Incorporation was filed with the Secretary of State of the State of Delaware |
|
| July 21, 2021 |
Consulting Agreement with Paul Manners Exhibit 10.4 RENOVORX CONSULTING AGREEMENT Effective Date: This Consulting Agreement (the “Agreement”) is made as of the Effective Date set forth above by and between RenovoRx, Inc, a Delaware corporation (“Client”) and the consultant named on the signature page hereto (“Consultant”). 1. Engagement of Services. Client may issue Project Assignments to Consultant in the form attached to this Agreeme |
|
| July 21, 2021 |
Form of Amended and Restated By-Laws of the Company, to be effective upon closing of the offering Exhibit 3.5 RENOVORX, INC. a Delaware Corporation (the “Corporation”) AMENDED AND RESTATED BYLAWS As Adopted [●], 2021 ARTICLE I MEETINGS OF STOCKHOLDERS Section 1.1 Place of Meetings. Meetings of stockholders shall be held at any place, within or outside the State of Delaware, designated by the board of directors of the Corporation (the “Board of Directors”). The Board of Directors may, in its so |
|
| July 21, 2021 |
Form of March 2020 Convertible Promissory Note Exhibit 10.9 THIS CONVERTIBLE PROMISSORY NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. NO SALE OR DISPOSITION MAY BE EFFECTED EXCEPT IN COMPLIANCE WITH RULE 144 UNDER SAID ACT OR AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL FOR THE HOLDER SATISFACTORY TO THE PAYOR THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE ACT OR RECEIPT OF A NO-AC |
|
| July 21, 2021 |
Form of Amendment to 2020 Convertible Promissory Note EX-10.10 17 ex10-10.htm Exhibit 10.10 RENOVORX, INC. AMENDMENT NO. 1 TO 2020 CONVERTIBLE PROMISSORY NOTES THIS AMENDMENT NO. 1 (this “Amendment”) to each of those certain Convertible Promissory Notes (collectively, the “Notes”) issued prior to the date hereof pursuant to that certain Note Purchase Agreement dated March 31, 2020, by and among RenovoRx, Inc. (the “Company”) and certain investors of |
|
| July 21, 2021 |
Amended Consulting Agreement with Ramtin Agah, MD Exhibit 10.3 RENOVORX, INC. August 22, 2019 Ramtin Agah, MD 1011 Sycamore Lane Menlo Park, CA 94025 Re: Second Amendment to Consulting Agreement Dear Ramtin: This Second Amendment effective September 1, 2019 (Effective Date) replaces the Amendment dated December 10, 2018 which replaced Exhibit A of the Consulting Agreement between you and the Company dated January 1, 2018 (the “Consulting Agreemen |
|
| July 21, 2021 |
Amended Consulting Agreement with Paul Manners Exhibit 10.5 Dec. 13, 2020 Paul Manners 943 Aquarius Way Oakland, CA 94611 Re: First Amendment to July 9, 2019 Consulting Agreement Dear Paul: As discussed, we have agreed to modify your July 9, 2019 Consulting Agreement as follows: Effective December 1, 2020, please change the compensation from $50 per hour to $150 per hour up to 30 hours per month. Consultant may not exceed 30 hours in a calenda |
|
| July 21, 2021 |
EX-3.4 5 ex3-4.htm exhibit 3.4 amended and restated BYLAWS OF RenovoRx, Inc. (A DELAWARE CORPORATION) amended and restated BYLAWS OF RenovoRx, Inc. (A DELAWARE CORPORATION) ARTICLE I Offices Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be in the City of Wilmington, County of New Castle. Section 2. Other Offices. The corporation shall also ha |
|
| July 21, 2021 |
Fifth Amended and Restated Certificate of Incorporation of Company EX-3.1 2 ex3-1.htm Exhibit 3.1 |
|
| July 21, 2021 |
Form of April 2021 Convertible Promissory Note EX-10.8 15 ex10-8.htm Exhibit 10.8 THIS CONVERTIBLE PROMISSORY NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. NO SALE OR DISPOSITION MAY BE EFFECTED EXCEPT IN COMPLIANCE WITH RULE 144 UNDER SAID ACT OR AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL FOR THE HOLDER SATISFACTORY TO THE PAYOR THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE ACT |
|
| July 21, 2021 |
Power of Attorney (included on the signature page) As filed with the Securities and Exchange Commission on July 21, 2021. No. 333- [ ] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 RenovoRx, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 27-1448452 (State or other jurisdiction of incorporation or organization) (Primary Standard Ind |
|
| July 21, 2021 |
Form of Warrant Agent Agreement (including the terms of the Warrants) Exhibit 4.2 WARRANT AGENT AGREEMENT This Warrant Agent Agreement (this ?Warrant Agreement?), dated as of , 2021 (the ?Issuance Date?) between RenovoRx, Inc., a company incorporated under the laws of the State of Delaware (the ?Company?), and Philadelphia Stock Transfer, Inc. (the ?Warrant Agent?). WHEREAS, pursuant to the terms of that certain Underwriting Agreement (?Underwriting Agreement?), dat |
|
| July 21, 2021 |
Consulting Agreement with Ramtin Agah, MD Exhibit 10.2 RENOVORX, INC. CONSULTING AGREEMENT This Consulting Agreement (the “Agreement”) is entered on this day of January 2013 (“Effective Date”) by and among RenovoRx, Inc., a Delaware corporation, and its successors or assignees (“Company”), and Ramtin Agah (referred to herein as “Consultant”) for the purpose of setting forth the terms and conditions by which the Company will acquire Consul |
|
| July 21, 2021 |
EX-10.11 18 ex10-11.htm Exhibit 10.11 [*] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. Master Supplv Agreement This Master Supply Agreement (the “Agreement” or “MSA”) is entered into on this 28th day of Oct. 2019 (the “Effective Date”) by and between Medical Murray, Inc., a |
|
| July 21, 2021 |
Form of Indemnification Agreement Exhibit 10.7 RENOVORX, Inc. INDEMNIFICATION AGREEMENT This INDEMNIFICATION AGREEMENT (“Agreement”) is made as of , 2021 by and between RenovoRX, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering the subject matter of this Agreement. RECITALS WHEREAS, highly competent p |
|
| June 15, 2021 |
Sheppard, Mullin, Richter & Hampton LLP DRSLTR 1 filename1.htm Sheppard, Mullin, Richter & Hampton LLP 30 Rockefeller Plaza New York, New York 10112-0015 212.653.8700 main 212.653.8701 fax www.sheppardmullin.com 212.634.3067 direct [email protected] June 15, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Re: RenovoRx, Inc. Amendment No. 1 to Draft |
|
| June 15, 2021 |
As confidentially submitted to the Securities and Exchange Commission on June 15, 2021 as Amendment No. |
|
| June 15, 2021 |
UNDERWRITER COMMON STOCK PURCHASE WARRANT RenovoRx, Inc. Exhibit 4.1 UNDERWRITER COMMON STOCK PURCHASE WARRANT RenovoRx, Inc. Warrant Shares: Initial Exercise Date: Issue Date: THIS UNDERWRITER COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after 1 (the ?Initia |
|
| June 15, 2021 |
RenovoRx, Inc. Amended and Restated 2013 Equity Incentive Plan Termination Date: January 22, 2023 EX-10.1 4 filename4.htm Exhibit 10.1 RenovoRx, Inc. Amended and Restated 2013 Equity Incentive Plan Termination Date: January 22, 2023 1. General. (a) Eligible Stock Award Recipients. The persons eligible to receive Stock Awards are Employees, Directors and Consultants. (b) Available Stock Awards. The Plan provides for the grant of the following Stock Awards: (i) Incentive Stock Options, (ii) Nons |
|
| June 15, 2021 |
Exhibit 3.2 CERTIFICATE OF AMENDMENT OF FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF RENOVORX, INC. RenovoRx, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), certifies that: 1. The name of the Company is RenovoRx, Inc. The Company’s original Certificate of Incorporation was filed with the Secretary of State of the State of Delaware |
|
| May 12, 2021 |
EX-3.1 2 filename2.htm Exhibit 3.1 |
|
| May 12, 2021 |
EX-3.2 3 filename3.htm Exhibit 3.2 SIXTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF RENOVORX, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) RenovoRx, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify |
|
| May 12, 2021 |
EX-10.8 11 filename11.htm Exhibit 10.8 THIS CONVERTIBLE PROMISSORY NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. NO SALE OR DISPOSITION MAY BE EFFECTED EXCEPT IN COMPLIANCE WITH RULE 144 UNDER SAID ACT OR AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL FOR THE HOLDER SATISFACTORY TO THE PAYOR THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE |
|
| May 12, 2021 |
RENOVORX, INC. AMENDMENT NO. 1 TO 2020 CONVERTIBLE PROMISSORY NOTES Exhibit 10.10 RENOVORX, INC. AMENDMENT NO. 1 TO 2020 CONVERTIBLE PROMISSORY NOTES THIS AMENDMENT NO. 1 (this ?Amendment?) to each of those certain Convertible Promissory Notes (collectively, the ?Notes?) issued prior to the date hereof pursuant to that certain Note Purchase Agreement dated March 31, 2020, by and among RenovoRx, Inc. (the ?Company?) and certain investors of the Company listed on th |
|
| May 12, 2021 |
EX-10.11 14 filename14.htm Exhibit 10.11 [*] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. Master Supplv Agreement This Master Supply Agreement (the “Agreement” or “MSA”) is entered into on this 28th day of Oct. 2019 (the “Effective Date”) by and between Medical Murray, Inc. |
|
| May 12, 2021 |
EX-10.1 6 filename6.htm Exhibit 10.1 RenovoRx, Inc. Amended and Restated 2013 Equity Incentive Plan Adopted by the Board of Directors: January 23, 2013 Approved by the Stockholders: January 23, 2013 Amended and Restated by the Board of Directors: December 6, 2015 Approved by the Stockholders: December 6, 2015 Termination Date: January 22, 2023 1. General. (a) Eligible Stock Award Recipients. The p |
|
| May 12, 2021 |
Exhibit 10.9 THIS CONVERTIBLE PROMISSORY NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. NO SALE OR DISPOSITION MAY BE EFFECTED EXCEPT IN COMPLIANCE WITH RULE 144 UNDER SAID ACT OR AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL FOR THE HOLDER SATISFACTORY TO THE PAYOR THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE ACT OR RECEIPT OF A NO-AC |
|
| May 12, 2021 |
Exhibit 10.3 RENOVORX, INC. August 22, 2019 Ramtin Agah, MD 1011 Sycamore Lane Menlo Park, CA 94025 Re: Second Amendment to Consulting Agreement Dear Ramtin: This Second Amendment effective September 1, 2019 (Effective Date) replaces the Amendment dated December 10, 2018 which replaced Exhibit A of the Consulting Agreement between you and the Company dated January 1, 2018 (the “Consulting Agreemen |
|
| May 12, 2021 |
EX-3.4 5 filename5.htm Exhibit 3.4 RENOVORX, INC. a Delaware Corporation (the “Corporation”) AMENDED AND RESTATED BYLAWS As Adopted [●], 2021 ARTICLE I MEETINGS OF STOCKHOLDERS Section 1.1 Place of Meetings. Meetings of stockholders shall be held at any place, within or outside the State of Delaware, designated by the board of directors of the Corporation (the “Board of Directors”). The Board of D |
|
| May 12, 2021 |
EX-3.3 4 filename4.htm exhibit 3.3 amended and restated BYLAWS OF RenovoRx, Inc. (A DELAWARE CORPORATION) amended and restated BYLAWS OF RenovoRx, Inc. (A DELAWARE CORPORATION) ARTICLE I Offices Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be in the City of Wilmington, County of New Castle. Section 2. Other Offices. The corporation shall als |
|
| May 12, 2021 |
Exhibit 10.5 Dec. 13, 2020 Paul Manners 943 Aquarius Way Oakland, CA 94611 Re: First Amendment to July 9, 2019 Consulting Agreement Dear Paul: As discussed, we have agreed to modify your July 9, 2019 Consulting Agreement as follows: Effective December 1, 2020, please change the compensation from $50 per hour to $150 per hour up to 30 hours per month. Consultant may not exceed 30 hours in a calenda |
|
| May 12, 2021 |
As confidentially submitted to the Securities and Exchange Commission on May 12, 2021 as Amendment No. |
|
| May 12, 2021 |
RENOVORX, INC. CONSULTING AGREEMENT EX-10.2 7 filename7.htm Exhibit 10.2 RENOVORX, INC. CONSULTING AGREEMENT This Consulting Agreement (the “Agreement”) is entered on this day of January 2013 (“Effective Date”) by and among RenovoRx, Inc., a Delaware corporation, and its successors or assignees (“Company”), and Ramtin Agah (referred to herein as “Consultant”) for the purpose of setting forth the terms and conditions by which the Com |
|
| May 12, 2021 |
Sheppard, Mullin, Richter & Hampton LLP DRSLTR 1 filename1.htm Sheppard, Mullin, Richter & Hampton LLP 30 Rockefeller Plaza New York, New York 10112-0015 212.653.8700 main 212.653.8701 fax www.sheppardmullin.com 212.634.3067 direct [email protected] May 12, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Re: RenovoRx, Inc. Draft Registration Stateme |
|
| May 12, 2021 |
EX-10.4 9 filename9.htm Exhibit 10.4 RENOVORX CONSULTING AGREEMENT Effective Date: This Consulting Agreement (the “Agreement”) is made as of the Effective Date set forth above by and between RenovoRx, Inc, a Delaware corporation (“Client”) and the consultant named on the signature page hereto (“Consultant”). 1. Engagement of Services. Client may issue Project Assignments to Consultant in the form |
|
| April 2, 2021 |
This is a confidential draft submission to the U.S. Securities and Exchange Commission on April 2, 2021 and is not being filed under the Securities Act of 1933, as amended. No. 333- [ ] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 RenovoRx, Inc. (Exact name of registrant as specified in its charter) Delawar |
